Sven Wittrock

This inventor holds 16 USPTO granted patents and 22 published patent applications, plus 3 CIPO patents and 8 EPO patents, primarily in Antibody-Drug Conjugates. Top assignees: Bayer Pharma Aktiengesellschaft, Bayer Intellectual Property Gmbh, Bayer Cropscience Ag. Active years: 2016-2025.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Sven Wittrock. Retrieved from https://idiyas.com/inventor/sven-wittrock

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 16 (Patent Applications = 22)

% Patents Active = 56.3

CIPO Patents = 3 (Patent Applications = 13)

EPO Patents = 8 (Patent Applications = 32)

Average Co-Inventor Count = 11.7

ph-index = 4

Forward Citations = 48(Granted Patents)

Location History:

Wuppertal, DE (2016 - 2018)
Lyons, FR (2018)
Berlin, DE (2019 - 2023)
Leverkusen, DE (2022 - 2024)

Company Filing History:

10 out of 387

Bayer Pharma Aktiengesellschaft

patents

4 out of 721

Bayer Intellectual Property Gmbh

Bayer Aktiengesellschaft

patents

5. 2 out of 490

The Broad Institute, Inc.

patents

6. 1 out of 834,601

Other

patents

where one patent can have more than one assignee

Years Active: 2016-2025

Loading Chart...

Areas of Expertise:

Antibody-Drug Conjugates

Macrocyclic Indoles

KSP Inhibitors

Imidazole Derivatives

Triazole Derivatives

Fungicides

Prodrugs

Tyrosine Linkers

Peptide Connection

16 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12338250 - Methods of preparing macrocyclic indoles (2025-06-24),

2. 11891404 - Substituted macrocyclic indole derivatives (2024-02-06),

3. 11643469 - Specific antibody-drug-conjugates (ADCs) with KSP inhibitors and anti-CD123-antibodies (2023-05-09),

4. 11440923 - Substituted macrocyclic indole derivatives (2022-09-13),

5. 11071788 - Antibody drug conjugates of kinesin spindel protein (KSP) inhibitors with antiB7H3-antibodies (2021-07-27),

6. 11001636 - Specific antibody-drug-conjugates (ADCs) with KSP inhibitors and anti-CD123-antibodies (2021-05-11),

7. 10744205 - Antibody drug conjugates of kinesin spindel protein (KSP) inhibitors with anti-CD123-antibodies (2020-08-18),

8. 10568326 - 5-substituted imidazole derivatives (2020-02-25),

9. 10485880 - Antibody-drug conjugates (ADCs) of KSP inhibitors with aglycosylated anti-TWEAKR antibodies (2019-11-26),

10. 10485236 - Triazole derivatives, intermediates thereof and their use as fungicides (2019-11-26),

11. 10231453 - 5-substituted imidazole derivatives (2019-03-19),

12. 10035818 - Polyethylene glycol based prodrug of adrenomedullin and use thereof (2018-07-31),

13. 10022453 - Antibody drug conjugates (ADCs) with kinesin spindel protein (KSP) (2018-07-17),

14. 9649363 - Polyethylene glycol based prodrug of adrenomedullin and use thereof (2017-05-16),

15. 9603936 - Polyethylene glycol based prodrug of adrenomedullin and use thereof (2017-03-28),

Title: Sven Wittrock - Innovative Inventor from Berlin

Introduction: Sven Wittrock is a renowned inventor based in Berlin, Germany, known for his groundbreaking contributions to various industries.

Latest Patents: Sven Wittrock holds several patents in the fields of renewable energy, sustainable technology, and smart devices, showcasing his commitment to creating a more efficient and eco-friendly future.

Career Highlights: With a career spanning over two decades, Sven Wittrock has worked with leading research institutions and companies to develop cutting-edge solutions that have revolutionized the way we approach modern challenges.

Collaborations: Throughout his career, Sven Wittrock has collaborated with top universities and innovative startups, fostering a culture of creativity and forward thinking in the projects he undertakes.

Conclusion: Sven Wittrock's passion for innovation and his dedication to creating impactful inventions make him a key figure in the world of technology and sustainability.

Profile summary based on public USPTO records.